Cancer Family
Lymphocytic Neoplasm
CI-CAN-00000223Explore in graph →
HematologicNon-malignant3,036 active trials72 approved drugs345 evidence items
- NCIt
- C7065
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000223Explore in graph →
Clinical trials
12,949 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02181738 | Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational)(CheckMate 205) | completed | Phase 2 | 294 | Bristol-Myers SquibbINDUSTRY | 10 | Nov 28, 2023 | clinicaltrials |
| NCT03255018 | Pembrolizumab in Relapsed and Refractory Gray-Zone Lymphoma (GZL), Primary Central Nervous System Lymphoma (PCNSL), and Other Extranodal Diffuse Large B-cell Lymphomas | completed | Phase 2 | 12 | National Cancer Institute (NCI)NIH | 1 | Nov 28, 2023 |
| clinicaltrials |
| NCT02834364 | BRAF/MEK Inhibition in Relapsed/Refractory Multiple Myeloma (BIRMA)(GMMG-BIRMA) | completed | Phase 2 | 12 | University of Heidelberg Medical CenterOTHER | 1 | Nov 24, 2023 | clinicaltrials |
| NCT03224507 | Monoclonal Antibody-Based Sequential Therapy for Deep Remission in Multiple Myeloma(MASTER) | completed | Phase 2 | 123 | University of Alabama at BirminghamOTHER | 1 | Nov 24, 2023 | clinicaltrials |
| NCT03900377 | Phase I/II Study of SyB L-0501RI in Combination With Rituximab to Treat Lymphoma | completed | Phase 1 / Phase 2 | 37 | SymBio PharmaceuticalsINDUSTRY | 1 | Nov 24, 2023 | clinicaltrials |
| NCT01193842 | Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas | completed | Phase 1 / Phase 2 | 107 | National Cancer Institute (NCI)NIH | 1 | Nov 21, 2023 | clinicaltrials |
| NCT02733042 | A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia(FUSION NHL 001) | completed | Phase 1 / Phase 2 | 106 | CelgeneINDUSTRY | 7 | Nov 18, 2023 | clinicaltrials |
| NCT04145531 | An Open-Label Study of JZP-458 (RC-P) in Patients With Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL) | completed | Phase 2 / Phase 3 | 229 | Jazz PharmaceuticalsINDUSTRY | 2 | Nov 18, 2023 | clinicaltrials |
| NCT00047060 | Stem Cell Transplant Therapy With Campath-1H for Treating Advanced Mycosis Fungoides and Sezary Syndrome | completed | Phase 1 / Phase 2 | 5 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Nov 14, 2023 | clinicaltrials |
| NCT00321555 | LMB-2 to Treat Hairy Cell Leukemia | completed | Phase 2 | 15 | National Cancer Institute (NCI)NIH | 1 | Nov 14, 2023 | clinicaltrials |
| NCT00924170 | Phase II Trial of LMB-2, Fludarabine and Cyclophosphamide for Adult T-Cell Leukemia | completed | Phase 1 / Phase 2 | 18 | National Cancer Institute (NCI)NIH | 1 | Nov 14, 2023 | clinicaltrials |
| NCT00734149 | Bortezomib With Melphalan and Prednisone for Multiple Myeloma(MVP) | completed | Phase 2 | 45 | Duke UniversityOTHER | 1 | Nov 7, 2023 | clinicaltrials |
| NCT01685008 | Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat Non-Hodgkin's Lymphoma (NHL) | completed | Phase 2 | 92 | MorphoSys AGINDUSTRY | 7 | Nov 7, 2023 | clinicaltrials |
| NCT02639559 | Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies | completed | Phase 2 | 50 | Washington University School of MedicineOTHER | 1 | Nov 7, 2023 | clinicaltrials |
| NCT03613727 | Therapeutic Use of Intravenous Vitamin C in Allogeneic Stem Cell Transplant Recipients | completed | Phase 2 | 61 | Virginia Commonwealth UniversityOTHER | 1 | Nov 7, 2023 | clinicaltrials |
| NCT02206425 | Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients | completed | Phase 1 / Phase 2 | 45 | OncotherapeuticsINDUSTRY | 1 | Oct 31, 2023 | clinicaltrials |
| NCT02547662 | Pomalidomide, Ixazomib Citrate, and Dexamethasone in Treating Patients With Previously Treated Multiple Myeloma or Plasma Cell Leukemia | completed | Phase 2 | 17 | Mayo ClinicOTHER | 1 | Oct 30, 2023 | clinicaltrials |
| NCT00777998 | Auto-Allo Tandem Stem Cell Transplantation for Patients With Multiple Myeloma | completed | Phase 2 | 221 | Universitätsklinikum Hamburg-EppendorfOTHER | 1 | Oct 27, 2023 | clinicaltrials |
| NCT02398240 | Brentuximab for Newly Diagnosed Hodgkin Disease | completed | Phase 2 | 40 | Mitchell CairoOTHER | 1 | Oct 26, 2023 | clinicaltrials |
| NCT03063632 | Testing the Combination of Two Experimental Drugs MK-3475 (Pembrolizumab) and Interferon-gamma for the Treatment of Mycosis Fungoides and Sézary Syndrome and Advanced Synovial Sarcoma | completed | Phase 2 | 28 | National Cancer Institute (NCI)NIH | 1 | Oct 25, 2023 | clinicaltrials |
| NCT00571662 | Safety and Efficacy of Pentostatin and Low Dose TBI With Allogenic Peripheral Blood Stem Cell Transplant | completed | Phase 2 | 76 | University of NebraskaOTHER | 1 | Oct 24, 2023 | clinicaltrials |
| NCT00611351 | Busulfan, Cyclophosphamide, & Antithymocyte Globulin Followed by Stem Cell Transplant in Treating Hematologic Cancer | completed | Phase 2 | 5 | University of NebraskaOTHER | 1 | Oct 23, 2023 | clinicaltrials |
| NCT02399085 | Open Label Study to Evaluate the Safety and Efficacy of Lenalidomide With MOR00208 in Patients With R-R DLBCL(L-MIND) | completed | Phase 2 | 81 | MorphoSys AGINDUSTRY | 10 | Oct 23, 2023 | clinicaltrials |
| NCT02869633 | Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant | completed | Phase 2 | 23 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Oct 23, 2023 | clinicaltrials |
| NCT02308280 | Nonmyeloablative Allogeneic Stem Cell Transplant Followed by Bortezomib in High-risk Multiple Myeloma Patients | completed | Phase 2 | 40 | Maisonneuve-Rosemont HospitalOTHER | 1 | Oct 19, 2023 | clinicaltrials |
| NCT03534180 | Venetoclax and Romidepsin in Treating Patients With Recurrent or Refractory Mature T-Cell Lymphoma | completed | Phase 2 | 12 | City of Hope Medical CenterOTHER | 1 | Oct 19, 2023 | clinicaltrials |
| NCT02304458 | Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas | completed | Phase 1 / Phase 2 | 140 | National Cancer Institute (NCI)NIH | 2 | Oct 17, 2023 | clinicaltrials |
| NCT03096782 | Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma | completed | Phase 2 | 6 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 11, 2023 | clinicaltrials |
| NCT01035463 | Lenalidomide Therapy After Chemotherapy & Stem Cell Transplant in Treating Chemotherapy Resistan Non-Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 74 | University of NebraskaOTHER | 1 | Oct 10, 2023 | clinicaltrials |
| NCT02509052 | Leflunomide in Treating Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 12 | City of Hope Medical CenterOTHER | 1 | Oct 10, 2023 | clinicaltrials |
| NCT02611323 | A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL) | completed | Phase 1 / Phase 2 | 133 | Hoffmann-La RocheINDUSTRY | 3 | Oct 10, 2023 | clinicaltrials |
| NCT00080886 | Rituximab, Carmustine; Cytarabine, Etoposide, & Melphalan; Stem Cell Transplantation for Non-Hodgkin's Lymphoma | completed | Phase 2 | 68 | University of NebraskaOTHER | 1 | Oct 6, 2023 | clinicaltrials |
| NCT02685826 | A Study of Durvalumab in Combination With Lenalidomide With and Without Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma | completed | Phase 1 / Phase 2 | 56 | CelgeneINDUSTRY | 8 | Oct 6, 2023 | clinicaltrials |
| NCT01431209 | Ruxolitinib Phosphate to Treat Diffuse Large B-Cell or Peripheral T-Cell Non-Hodgkin Lymphoma After Stem Cell Transplant | completed | Phase 2 | 71 | University of NebraskaOTHER | 1 | Oct 5, 2023 | clinicaltrials |
| NCT02874404 | TGR-1202 and Ibrutinib in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma | completed | Phase 2 | 13 | University of NebraskaOTHER | 1 | Oct 5, 2023 | clinicaltrials |
| NCT01060384 | Study of Lenalidomide and Ofatumumab for the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma | completed | Phase 1 / Phase 2 | 46 | University of NebraskaOTHER | 1 | Oct 4, 2023 | clinicaltrials |
| NCT00081809 | A Safety and Effectiveness Study of Vaccine Therapy in Patients With Indolent Lymphoma | completed | Phase 2 | 35 | Agenus Inc.INDUSTRY | 1 | Sep 28, 2023 | clinicaltrials |
| NCT00571493 | VELCADE®-BEAM and Autologous Hematopoietic Stem Cell Transplantation for Non-Hodgkin's Lymphoma, or Mantle Cell Lymphoma | completed | Phase 1 / Phase 2 | 42 | University of NebraskaOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT00574496 | Combination Chemotherapy Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or High-Risk Primary Refractory Hodgkin Lymphoma | completed | Phase 2 | 25 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT00610883 | LSA4 Protocol for the Treatment of Advanced Pediatric and Adolescent Non-Hodgkins Lymphoma | completed | Phase 2 | 17 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT03571308 | A Combination of Acalabrutinib With R-CHOP for Patient Diffuse Large B-cell Lymphoma (DLBCL)(ACCEPT) | completed | Phase 1 / Phase 2 | 39 | University Hospital Southampton NHS Foundation TrustOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT00550615 | Dasatinib in Relapsed or Refractory Non-Hodgkin's Lymphoma | completed | Phase 1 / Phase 2 | 38 | University of NebraskaOTHER | 1 | Sep 26, 2023 | clinicaltrials |
| NCT03155100 | Carfilzomib + Elotuzumab + Dexamethasone for Relapsed Multiple Myeloma After 1-3 Prior Treatment Lines(KEd) | completed | Phase 2 | 15 | Raija SilvennoinenOTHER | 2 | Sep 26, 2023 | clinicaltrials |
| NCT00352027 | Chemotherapy With Low-Dose Radiation for Pediatric Hodgkin Lymphoma | completed | Phase 2 | 81 | St. Jude Children's Research HospitalOTHER | 1 | Sep 22, 2023 | clinicaltrials |
| NCT01336933 | Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma | completed | Phase 2 | 34 | University of NebraskaOTHER | 1 | Sep 22, 2023 | clinicaltrials |
| NCT00003838 | Specialized Blood Cell Transplants for Cancers of the Blood and Bone Marrow | completed | Phase 2 | 202 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Sep 21, 2023 | clinicaltrials |
| NCT01739309 | Study of LY2835219 for Mantle Cell Lymphoma | completed | Phase 2 | 28 | Eli Lilly and CompanyINDUSTRY | 2 | Sep 21, 2023 | clinicaltrials |
| NCT02661035 | Allo HSCT Using RIC for Hematological Diseases | completed | Phase 2 | 156 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT03202628 | Ixazomib Citrate, Pomalidomide, Dexamethasone, Stem Cell Transplant in Treating Relapsed or Refractory Multiple Myeloma | completed | Phase 2 | 8 | Mayo ClinicOTHER | 1 | Sep 21, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Nov 28, 2023source: clinicaltrials